ACE-031 vs Anserine

Evidence-based comparison. Updated 2026.

ACE-031 and Anserine target muscle health through entirely different mechanisms. ACE-031 is a research-stage fusion protein designed to promote muscle mass and reduce wasting by blocking myostatin and activin A signaling, making it relevant to dystrophic or cachexic conditions. Anserine is a dipeptide buffer and antioxidant suited to exercise recovery and fatigue reduction. Choose ACE-031 for mass and regeneration research; choose Anserine for performance and recovery contexts.

Side by side

	ACE-031	Anserine
Evidence	BEvidenceGrade BSmaller human trials or observational studies, or approved in 30+ countries	CEvidenceGrade CMainly animal or in-vitro studies, with limited human data
Regulatory	Research onlyResearch onlyNo regulatory approval in any major jurisdiction. For research use only	Research onlyResearch onlyNo regulatory approval in any major jurisdiction. For research use only
Benefits	Increases skeletal muscle mass and strength Reduces muscle wasting in dystrophic conditions Improves muscle regeneration capacity Enhances exercise tolerance Reduces circulating myostatin levels	Reduces muscle fatigue and lactate accumulation Provides antioxidant protection in muscle tissue Supports post-exercise muscle recovery May enhance exercise endurance capacity Anti-inflammatory effects in muscle
Dosage	1-3 mg/kg, Every 2 weeks	500-1000 mg, 1-2x daily
Route	Intravenous, Subcutaneous	Subcutaneous
Category	Muscle Growth & Performance	Muscle Growth & Performance

Full research page

ACE-031

Full research page

Anserine

Which should you choose

ACE-031 operates at the hormonal-signaling level by removing inhibitory ligands that suppress muscle growth, while Anserine works intracellularly as a pH buffer and ROS scavenger during and after exercise. These are fundamentally different intervention points: one addresses the ceiling on muscle mass, the other addresses the metabolic cost of using that muscle.

Choose ACE-031 when

Research focus involves pathological muscle wasting conditions such as muscular dystrophy, cachexia, or sarcopenia where myostatin suppression is the primary target.
The goal is to study increases in skeletal muscle mass and cross-sectional hypertrophy rather than acute performance metrics.
The experimental model requires measurable reductions in circulating myostatin or activin A as a pharmacodynamic endpoint.

Choose Anserine when

Research focus centers on exercise-induced fatigue, lactate accumulation, or intramuscular buffering capacity during high-intensity protocols.
The subject population is healthy or athletic rather than clinically muscle-wasted, where antioxidant and anti-inflammatory support during recovery is the primary question.
A lower-risk, naturally occurring dipeptide is preferred given its food-derived origin and comparatively benign tolerability profile in available studies.

Stacking ACE-031 with Anserine is not an established research protocol, but the combination is mechanistically non-redundant: ACE-031 may support structural muscle growth while Anserine addresses the oxidative and acidic stress of training, suggesting complementary rather than overlapping roles.

Questions people ask

Do ACE-031 and Anserine affect the same physiological pathway, or are they truly independent in their muscle-related actions?

They act on entirely separate pathways. ACE-031 intercepts TGF-beta superfamily signaling by binding myostatin and activin A extracellularly, thereby removing a systemic brake on muscle protein synthesis. Anserine functions intracellularly within muscle fibers as a histidine dipeptide buffer and antioxidant, neutralizing hydrogen ions and reactive oxygen species. There is no known crosstalk between these mechanisms, making them independent interventions on distinct aspects of muscle physiology.

How do the research timelines and effect onset differ between ACE-031 and Anserine?

ACE-031 produces measurable changes in muscle volume and circulating myostatin over weeks to months, consistent with the time required for structural hypertrophy and receptor-level signaling shifts. Anserine's effects on buffering capacity and oxidative stress markers can be observed acutely within a single exercise session, with chronic supplementation studies typically running four to eight weeks to assess endurance and recovery outcomes. Researchers should account for these very different temporal windows when designing comparative or combination protocols.

Could a researcher reasonably combine ACE-031 and Anserine in the same study, and what would be the rationale?

A combination protocol is mechanistically plausible because ACE-031 addresses muscle mass ceiling by removing inhibitory growth signals, while Anserine addresses the metabolic and oxidative environment during exercise bouts. A study could hypothesize that ACE-031-driven hypertrophy is better preserved or expressed when training-induced fatigue and ROS are simultaneously managed by Anserine. However, no published human or animal trials have formally tested this stack, so any combined use remains speculative and would require independent safety and efficacy evaluation.

Which compound carries greater regulatory and safety uncertainty for research use?

ACE-031 carries substantially greater regulatory and safety uncertainty. Its clinical trials were halted partly due to adverse events including nosebleeds and telangiectasia, attributed to off-target effects on activin and BMP signaling beyond muscle tissue. Anserine, being a naturally occurring dipeptide found in poultry and fish, has a longer history of dietary exposure and a more favorable tolerability profile in available studies, though formal regulatory approval for therapeutic use does not exist for either compound. Researchers should treat ACE-031 as carrying a higher risk profile.

Not sure which fits your research goals?

Use the goal finder

Answer three questions and get a peptide recommendation ranked by evidence grade.

Find my peptide